VAUGHAN, ON , Sept. 21, 2022 /CNW/ — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that data from the National Eye Institute’s (NEI) 10-Year Follow-on Research Results of the Age-Related Eye Disease Study 2 (AREDS2), which was recently published in JAMA Ophthalmology , will be reviewed and discussed among leading vision care professionals during a live, complimentary webinar, ” More InSight: A Closer Look at the Brand new AREDS2 Data and What It Means For Patients ” on Tuesday, Oct. 18, 2022 , through 8: 00-9: 00 p. m. ET .

Bausch + Lomb (PRNewsfoto/Bausch + Lomb Corporation)

The hour-long webinar is specifically designed to help  eye care professionals understand the new results plus come away with knowledge of how it can be integrated into practice in order to support Age-related Macular Degeneration (AMD) patients. The session, which will be moderated by Paul Karpecki, O. D., clinical director, Kentucky Eye Institute, will also spotlight medical insights from Emily Chew , M. D., chair, AREDS2 Study, NEI, and feature expert commentary through panelists Jeffry Gerson , O. D., Grin Vision Care, Kansas City, Mo. , plus Rishi Singh , M. D., president, Cleveland Clinic Martin North and South Hospitals, Cleveland .

“With the AREDS2 10 Year Follow-on Research, we now have more than two decades of research demonstrating the impact that will a specific nutrient formula can have on patients with moderate to advanced AMD, ” said Dr. Chew. “The purpose of the particular ‘More InSight’ webinar will be to discuss that impact – which further supports NEI’s current recommendation of a specific combination of six nutrients, including lutein, zeaxanthin and antioxidants, and how doctors can implement these learnings in daily practice. ”

“Together with Drs. Chew, Gerson, Karpecki plus Singh, we look forward to providing eye treatment professionals with the opportunity to learn more about these types of latest study results as well as obtain insightful takeaways that can enhance their AMD practices and support the millions of people impacted  by moderate in order to advanced AMD, ” said Joe Gordon, president, Global Consumer, Surgical and Vision Care, Bausch + Lomb.

To register for the ‘More InSight’ webinar, visit www.reviewofophthalmology.com/more-insight-1018 .

About AMD
Age-related Macular Deterioration (AMD) is usually a progressive eye condition that impacts central vision and is definitely a top cause of blindness in adults 50 years of age and older. Early-stage ADVANCED MICRO DEVICES often does not present any symptoms or changes in eyesight, as signs and symptoms usually appear gradually over time. This progressive condition can impact one or both eyes, causing individuals to have difficulty with daily activities like driving, reading or even recognizing the particular faces associated with loved ones. two

About the AREDS, AREDS2 and 10-Year Follow-on AREDS2 Study Results
The AREDS plus AREDS2 studies are landmark clinical studies conducted over 20 years simply by the NEI. The AREDS study inside 2001 demonstrated that taking a specific mixture of antioxidants and zinc could help reduce the risk of progression associated with AMD in those with average to sophisticated AMD. In 2012, the particular NEI completed the AREDS2 study, which usually tested several changes to the formulation, such as adding omega-3 fatty acids, substituting lutein and zeaxanthin for beta-carotene, and/or reducing zinc. The particular current AREDS2 nutrient method recommended by the NEI is the result of this study.

The NEI 10-Year Follow-on Research results evaluated the long-term results of participants who were involved in the AREDS2 research. Consisting of 3, 883 people (6, 351 study eyes) with moderate to superior AMD more than a 10-year period, the particular follow-on study further validates the original findings associated with the AREDS2 formulation with lutein plus zeaxanthin, demonstrating an incremental reduction within risk of the progression to late-stage AMD. 1

Regarding Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift associated with sight for millions of people around the world – from the moment of birth through every phase associated with life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, attention care products, ophthalmic pharmaceuticals, over-the-counter items and ophthalmic surgical devices and instruments. Founded inside 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint along with more than 12, 000 employees plus a presence in nearly 100 countries. Bausch + Lomb can be headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey . For more information, visit  www.bausch.com   and connect with us upon Twitter , LinkedIn , Facebook plus Instagram .

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the particular use of the words “anticipates, ” “hopes, ” “expects, ” “intends, ” “plans, ” “should, ” “could, ” “would, ” “may, ” “believes, ” “estimates, ” “potential, ” “target, ” or “continue” and variations or even similar expressions. These statements are based upon the current expectations plus beliefs associated with management and are subject to certain risks and uncertainties that could trigger actual results to differ materially from those described in the forward-looking statements. These dangers and questions include, but are not limited to, the risks and uncertainties discussed inside Bausch + Lomb’s filings with the particular U. S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited in order to, risks plus uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that will pandemic and its potential effects, the severity, duration and future effect of which are highly uncertain plus cannot be predicted, and which usually may have a material adverse impact on Bausch + Lomb, including but not small to its project development timelines, launches and costs (which might increase). Readers are cautioned not in order to place undue reliance upon any of these forward-looking statements. These forward-looking claims speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update some of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

*Compared to individuals taking the particular original AREDs formula

References

  1. Chew up EY, Clemons TE, Agrón E, et al. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids in order to the AREDS Supplements on Age-Related Macular Degeneration Progression:   AREDS2 Report 28.   JAMA Ophthalmology.   2022; 140(7): 692–698. doi: 10. 1001/jamaophthalmol. 2022. 1640National Eye Institute: Age-Related Macular Degeneration .

  2. Based upon the AREDS and AREDS2 studies.

AREDS and AREDS2 are registered trademarks of the United States Department associated with Health and Human Services (HHS).  
Any other product/brand names are trademarks of the respective owners.  
© 2022 Bausch & Lomb Incorporated or the affiliates.  
PV2. 0108. USA. 22

Investor Contacts:

Media Contacts:

Arthur Shannon

Lainie Keller

arthur. [email protected] com  

lainie. [email protected] com

(908) 927-1198

Allison Ryan                 

Kristy  Marks                                                                                     

allison. [email protected] possuindo        

kristy. [email protected] com

(877) 354-3705 (toll free)         

(908) 927-0683                                                                

(908) 927-0735

Cision

Cision

View original content to download multimedia: https://www.prnewswire.com/news-releases/bausch–lomb-announces-webinar-for-eye-care-professionals-on-new-areds2-study-findings-301629071.html

SOURCE Bausch + Lomb Company

Cision

Cision

See original happy to download media: http://www.newswire.ca/en/releases/archive/September2022/21/c4852.html

Leave a Reply

Your email address will not be published.